[1]Hoofnagle JH, Doo E. Letter to the editor: a multi-society delphi consensus statement on new fatty liver disease nomenclature[J]. Hepatology, 2024, 79: E91-E92. [2]Lazarus JV, Newsome PN, Francque SM, et al. Reply: a multi-society delphi consensus statement on new fatty liver disease nomenclature[J]. Hepatology, 2024, 79: E93-E94. [3]Miao L, Targher G, Byrne CD, et al. Current status and future trends of the global burden of MASLD[J]. Trends Endocrinol Metab, 2024,35:697-707. [4]Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver[J]. J Clin Transl Hepatol, 2022, 10: 329-338. [5]Simon TG, Wilechansky RM, Stoyanova S, et al. Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: a randomized clinical trial[J]. JAMA, 2024, 331: 920-929. [6]史冬雪,原佳琪,丁宝锋,等. 非酒精性脂肪肝病模型小鼠的肝脏病理变化及肝细胞获取方法[J]. 基础医学与临床, 2022, 42: 890-895. [7]Garcia MC, Amankwa-Sakyi M, Flynn TJ. Cellular glutathione in fatty liver in vitro models[J]. Toxicol In Vitro, 2011, 25: 1501-1506. [8]Hendriks D, Brouwers JF, Hamer K, et al. Engineered human hepatocyte organoids enable crispr-based target discovery and drug screening for steatosis[J]. Nat Biotechnol, 2023, 41: 1567-1581. [9]Seglen PO. Preparation of isolated rat liver cells[J]. Method Cell Biol, 1976,13: 29-83. [10]罗燕,和兴萍,李雪,等. 几种细胞脂肪变性模型的建立与比较分析[J]. 中华中医药学刊, 2017, 35: 2074-2077. [11]Chakrabarti SK, Cole BK, Wen Y, et al. 12/15-lipoxygenase products induce inflammation and impair insulin signaling in 3t3-l1 adipocytes[J]. Obesity (Silver Spring), 2009, 17: 1657-1663. |